Time & Date: 4 September, 11:30 – 12:30 CEST
Chairperson: G. Staurenghi ITALY & M.S. Figueroa SPAIN
Speakers & Presentations:
G. Staurenghi ITALY
11:30 Welcome
M.S. Figueroa SPAIN
11:32 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Patient Case Profiles From the Phase 3 TENAYA and LUCERNE Trials
D. Zur ISRAEL
11:38 Algorithm-Based Management of Age-related Macular Degeneration – A British-Israeli Collaboration. The BI-AMD Study
G. Staurenghi ITALY
11:44 Relationship Between Number of Intermediate or Large Drusen and Geographic Atrophy Lesion Growth Rate in the Sham Groups of the OAKS, DERBY, and FILLY Trials
O. Nanegrungsunk THAILAND
11:50 Association between Hypertransmission Defects and Progression in Eyes with Intermediate Age-related Macular Degeneration
M. Cozzi ITALY
11:56 Macular neovascularization area progression in eyes with neovascular age-related macular degeneration treated with vascular endothelial grow factors inhibitors using a treat-and-extend or a Pro re nata regimen.
Four-year results of the LANEX study
M. Battista ITALY
12:02 Inner and Outer Choroidal changes in the Fellow Eye of Patients with Unilateral Central Serous Chorioretinopathy
R. Liegl GERMANY
12:08 Quantitative Autofluorescence in patients with central serous chorioretinopathy
N. Sahoo INDIA
12:14 Ten-year follow-up of structural and functional changes in Central Serous Chorioretinopathy: a multimodal imaging-based studyn
U. Limon TURKEY
12:20 Elevated serum fibrinogen/albumin ratios in patients with acute central serous chorioretinopathy
All Faculty
12:26 Discussion
